Skip to main content

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

[widgetkit id="1" name="CC Event Nav"]

Reviewing the Demographics and First-Line Treatment Patterns in Patients with CLL

Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Changes in Clinical Stage Identify Different Response Categories Among Patients in iwCLL PR: Analysis of CLL Patients on the RESONATE Study

PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter’s Transformation: An Updated Report from a Phase 2 Trial (MC1485)

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Identification of Baseline Characteristics That Predict Good Outcome of alloHCT in Young CLL Patients - A Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Preclinical Analyses Support Clinical Investigation of Combined Anti-CD19 CAR-T Cell, JCAR017 with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia

Long-Term Follow-Up of Chlorambucil plus Rituximab Combination as Frontline Therapy for Elderly and/or Unfit Patients with CLL, Including Risk Stratification

Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center

Initial Results of a Multicenter, Phase II Study of Ibrutinib plus FCR (iFCR) as Frontline Therapy for Younger CLL Patients

Page 20 of 25
Results 191 - 200 of 242